Top

Published in:

01-01-2021 | Breast Cancer | Brief Report

Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors

Authors: Pietro Sollena, Vasiliki Nikolaou, Nikolaos Soupos, Elias Kotteas, Dimitra Voudouri, Alexandros J. Stratigos, Davide Fattore, Maria Carmela Annunziata, Armando Orlandi, Lucia Di Nardo, Zoe Apalla, Florian Deilhes, Maria Concetta Romano, Gabriella Fabbrocini, Vincent Sibaud, Ketty Peris, the European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Abstract

Purpose

Introduction of cyclin-dependent inhibitors was a milestone in therapeutics for patients with estrogen receptor+/HER2− metastatic breast cancer. Despite the wide use of such agents and remarkable improvement of survival rates, drug-related adverse events are not yet fully characterized. We describe vitiligo-like lesions as a new adverse event occurring in patients with advanced breast cancer treated with cyclin-dependent inhibitors.

Methods

We performed an international retrospective study including patients with advanced breast cancer who developed vitiligo-like lesions during treatment with cyclin-dependent kinases 4 and 6 inhibitors, in the period January 2018–December 2019. Patients > 18 years, both males and females, were recruited at six Dermatology Departments located in Italy (3), France (1) and Greece (2). We evaluated epidemiological and clinical characteristics, impact on quality of life and outcome of vitiligo-like lesions in patients treated with cyclin-dependent 4 and 6 inhibitors. The percentage of skin involved by vitiligo-like lesions was assessed using the Body Surface Area (BSA) score. Changes in patients’ quality of life were investigated through the evaluation of the Dermatology Life Quality Index (DLQI) questionnaire.

Results

Sixteen women (median age: 62.5 years; range 40–79 years) treated with cyclin-dependent kinases 4 and 6 inhibitors for advanced breast cancer presented with vitiligo-like lesions during follow-up visits. Cutaneous lesions consisted of white, irregular macules and patches located mainly on sun-exposed areas in 11/16 patients or diffuse to the entire body surface in 5/16. Cutaneous lesions clearly impaired the quality of life of patients tested (DLQI ≥ 10).

Conclusions

We present for the first time, to our knowledge, a case series of vitiligo-like lesions developing in patients with advanced breast cancer treated with cyclin-dependent kinases 4 and 6 inhibitors. We showed that such lesions further impair the patients’ quality of life and their treatment is challenging.

Yan L, Rosen N, Arteaga C (2011) Targeted cancer therapies. Chin J Cancer 30(1):1–4. https://doi.org/10.5732/cjc.010.10553CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627CrossRefPubMedPubMedCentral

Gao JJ, Cheng J, Bloomquist E et al (2020) CDK 4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis. Lancet Oncol 21(2):250–260. https://doi.org/10.1016/S1470-2045(19)30804-6CrossRefPubMed

Choi YJ, Li X, Hydbring P et al (2012) The requirement for cyclin D function in tumor maintenance. Cancer Cell 22(4):438–451. https://doi.org/10.1016/j.ccr.2012.09.015CrossRefPubMedPubMedCentral

Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748CrossRefPubMed

Tripathy D, Im SA, Colleoni M (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904–915CrossRefPubMed

Im SA, Lu YS, Bardia A, Harbeck N et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307–316CrossRefPubMed

Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936CrossRefPubMed

Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226):817–827. https://doi.org/10.1016/S0140-6736(20)30165-3CrossRefPubMed

10.

Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126–1134. https://doi.org/10.1634/theoncologist.2013-0193CrossRefPubMedPubMedCentral

11.

Lasheen S, Shohdy KS, Kassem L, Abdel-Rahman O (2017) Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther 17(9):851–856. https://doi.org/10.1080/14737140.2017.1355242CrossRefPubMed

12.

Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77(1):1–13. https://doi.org/10.1016/j.jaad.2016.10.048CrossRefPubMed

13.

Zarogoulidis P, Huang H, Tsiouda T et al (2017) Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. Respir Med Case Rep 26(22):283–286. https://doi.org/10.1016/j.rmcr.2017.10.006CrossRef

14.

Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME (2017) Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol 77(5):902–910.e2. https://doi.org/10.1016/j.jaad.2017.06.044CrossRefPubMedPubMedCentral

15.

Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139–145PubMed

16.

Mohammed GF, Gomaa AH, Al-Dhubaibi MS (2015) Highlights in pathogenesis of vitiligo. World J Clin Cases 3(3):221–230. https://doi.org/10.12998/wjcc.v3.i3.221CrossRefPubMedPubMedCentral

17.

Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J (2018) Vitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J Am Acad Dermatol 78(1):e17–e18. https://doi.org/10.1016/j.jaad.2017.08.028CrossRefPubMed

18.

Zhou M, Lin F, Xu W, Jin R, Xu A (2018) Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep 18(3):3469–3475. https://doi.org/10.3892/mmr.2018.9299CrossRefPubMed

19.

Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 3(10):1758835918793326. https://doi.org/10.1177/1758835918793326CrossRef

20.

Kim YJ, Cohen PR (2020) Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb) 10(1):221–229. https://doi.org/10.1007/s13555-020-00353-3CrossRef

21.

Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773–781. https://doi.org/10.1200/JCO.2014.57.4756CrossRefPubMed

22.

Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45–51. https://doi.org/10.1001/jamadermatol.2015.2707CrossRefPubMed

Title: Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors
Authors: Pietro Sollena
Vasiliki Nikolaou
Nikolaos Soupos
Elias Kotteas
Dimitra Voudouri
Alexandros J. Stratigos
Davide Fattore
Maria Carmela Annunziata
Armando Orlandi
Lucia Di Nardo
Zoe Apalla
Florian Deilhes
Maria Concetta Romano
Gabriella Fabbrocini
Vincent Sibaud
Ketty Peris
the European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Vitiligo
Letrozole
Pruritus
Published in: Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05914-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia

Impact of patients’ refusal to undergo adjuvant treatment measures on survival

Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study

Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype

Keynote webinar | Spotlight on antibody–drug conjugates in cancer